25 July 2018
: Case report
Fatal Disseminated Kaposi’s Sarcoma in Two Patients with Human Immunodeficiency Virus (HIV) Infection
Unusual clinical course
Rafaela Barbirato Fardin1ABCDEF, Luiz Arhur Calheiros Leite2ABCDEF*, Luanna Mayara dos Santos Bezerra1B, Priscilla Maris Pereira Alves1CDEF, Layanne Lima dos Santos1BCD, Marília de Andrade Salvá1CDE, Antônio Luiz Soares Moura Rezende Filho1BCD, Gilberto Salustiano Lima2BD, Juliana de Amorim Matos1CD, Sônia Maria Soares Ferreira1B, Ducy Lily Joazeiro de Farias Costa1BDOI: 10.12659/AJCR.910004
Am J Case Rep 2018; 19:868-874
Abstract
BACKGROUND: Kaposi’s sarcoma (KS) is a common condition in patients with human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS). In these patients, the occurrence of KS is reduced by treatment with highly active antiretroviral therapy (HAART). Fatal and disseminated KS is presented in two patients with HIV/AIDS.
CASE REPORT: A 25-year-old man and a 30-year-old man with HIV/AIDS presented with KS affecting the skin, oral cavity, gastrointestinal tract, liver, lungs, kidneys, adrenal glands, and bone. Both patients had a rapidly deteriorating clinical course associated with a low CD4 count and developed respiratory failure and death.
CONCLUSIONS: Fatal disseminated KS is associated with severe immunosuppression due to with a low CD4 count. The presentation of these two cases highlights the potentially aggressive clinical course of KS in patients with HIV/AIDS and reinforces the need for early diagnosis and rapid treatment with HAART.
Keywords: Antiretroviral Therapy, Highly Active, HIV, Sarcoma, Kaposi
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947185
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946911
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.947730
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.946625
Most Viewed Current Articles
21 Jun 2024 : Case report
98,573
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
52,979
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133
20 Nov 2023 : Case report
33,819
DOI :10.12659/AJCR.941424
Am J Case Rep 2023; 24:e941424
07 Jul 2023 : Case report
23,921
DOI :10.12659/AJCR.940200
Am J Case Rep 2023; 24:e940200